Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00420927 · ClinicalTrials.gov registry record · Phase 4
Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis
A Phase 4 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,032
- Enrollment target
NCT00420927 is a Phase 4 study that has completed, run by Abbott. The registered enrollment target is 1,032 participants.
The verdict
NCT00420927, a Phase 4 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,032 participants
- Enrollment target
Study Summary
This study compared the safety and efficacy of combination therapy with adalimumab plus methotrexate (MTX) to that of MTX monotherapy (i.e., placebo plus MTX) in subjects with early rheumatoid arthritis (RA).
Interventions
- BIOLOGICAL placebo
- DRUG methotrexate
- BIOLOGICAL adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,032 participants |
| Start Date | 2006-12 |
| Est. Completion | 2010-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00420927
The ClinicalTrials.gov registry entry for NCT00420927 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,032 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00420927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00420927 about?
NCT00420927 is a clinical study titled "Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis". This study compared the safety and efficacy of combination therapy with adalimumab plus methotrexate (MTX) to that of MTX monotherapy (i.e., placebo plus MTX) in subjects with early rheumatoid arthritis (RA).
What is the current status of trial NCT00420927?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,032 participants. The study started on 2006-12. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00420927?
The interventions under investigation include: placebo (BIOLOGICAL), methotrexate (DRUG), adalimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00420927?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.